Related Experiment Video
Updated: May 11, 2026
Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
Published on: March 30, 2018
[Immunophenotype analysis of leukemic mantle cell lymphoma]
1Department of Hematology, Nanjing Medical University First Affiliated Hospital, Nanjing, Jiangsu Province, China.
Insights
Mantle cell lymphoma (MCL) often presents atypically in its leukemic phase. New biomarkers CD200 and CD148 show promise in distinguishing MCL from other B-cell disorders.
Area of Science:
- Hematology
- Oncology
- Immunophenotyping
Background:
- Mantle cell lymphoma (MCL) is a challenging mature B-cell neoplasm with poor prognosis, frequently misdiagnosed.
- Diagnosis is complicated by its frequent presentation in the leukemic phase, often identified via flow cytometry and cytogenetics.
Purpose of the Study:
- To investigate the immunophenotypic characteristics of leukemic Mantle cell lymphoma.
- To evaluate the utility of novel biomarkers CD200 and CD148 in differentiating MCL from other chronic B-cell lymphoproliferative diseases.
Main Methods:
- Retrospective analysis of immunophenotype data from 22 leukemic MCL patients.
- Utilized four-color flow cytometry to analyze expression of various cell surface markers (CD3, CD5, CD19, CD20, CD22, CD23, FMC7, CD148, CD200, etc.).
- Confirmed t(11;14) translocation using fluorescence in situ hybridization.
Main Results:
- All patients expressed CD19, CD5, CD20 (high), and monoclonal sIg.
- CD22 was weakly expressed in 17 patients; CD23 in 6; FMC7 in 12.
- CD148 was positive in all 18 patients tested (median MFI: 337), while CD200 showed variable expression (negative in 11, weak in 7).
Conclusions:
- Leukemic Mantle cell lymphoma exhibits atypical immunophenotypes, necessitating comprehensive diagnostic approaches including morphology, immunophenotype, and cytogenetics.
- CD200 and CD148 emerge as potential biomarkers for differentiating MCL from chronic B-cell lymphoproliferative disorders.
Abstract:
Mantle cell lymphoma (MCL) is a kind of mature B-cell neoplasms with significantly poor prognosis and is usually misdiagnosed. With the development of flow cytometry and cytogenetic technique, most patients were at leukemic phase when diagnosed. This study was purposed to investigate the immunophenotypes of MCL, the immunophenotype information of 22 leukemic MCL patients was analyzed retrospectively. All the patients were conformed t(11;14) translocation by fluorescence in situ hybridization. Immunophenotypes were detected by a four-color flow cytometry including CD3, CD4, CD5, CD8, CD10, CD19, CD20, CD22, CD23, CD25, CD38, CD103, CD148, CD200, FMC7, ZAP-70, κ, λ. The results showed that CD19, CD5, CD20 and monoclonal sIg expressed in all 22 patients with CD20 high expression; CD22 expressed weakly in 17 patients; CD23 expressed in 6 patients including 2 cases highly expressed; FMC7 expressed in 12 patients. 5 patients were 4-point score and 17 patients had a score less than 4 according to CLL scoring system. CD148 and CD200 were detected in 18 patients, in which CD200 expressed negatively in 11 patients, CD200 expressed weakly in 7 patients with median fluorescence intensity (MFI) 25.8 (6.6 - 254.26); CD148 expressed positively in all 18 patients with median MFI: 337 (73.4 - 1341.9). It is concluded that the atypical immunophenotype is common in leukemia MCL, thereby the diagnosis of MCL needs comprehensively analyze with morphocytology, immunophenotype and cytogenetic, CD200 and CD148 as new bio-markers can differentiate MCL from chronic B cell lymphoproliferative disease.
